This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights Sanofi, Merck, Novartis, Pfizer and J&J
by Zacks Equity Research
Sanofi, Merck, Novartis, Pfizer and J&J are part of Zacks top Analyst Blog.
Pharma Stock Roundup: FDA Panel Backs Updated COVID Jabs, EU Nod for SNY, MRK Drugs
by Kinjel Shah
An FDA panel recommends updating COVID-19 booster shots. EU approvals for Sanofi's (SNY) two new drugs and expanded use of Merck's (MRK) Keytruda and Novartis' (NVS) Cosentyx.
Gilead's (GILD) Yescarta Gets EC Nod for Follicular Lymphoma
by Zacks Equity Research
Gilead's (GILD) cell therapy, Yescarta, gets approval in Europe for a third indication- adult patients with relapsed or refractory follicular lymphoma after three or more lines of systemic therapy.
Q2 Earnings Season Preview and Featured Analyst Reports for J&J, AMD & Union Pacific
by Sheraz Mian
Today's Research Daily features preview of the Q2 earnings season and new research reports for J&J (JNJ), AMD (AMD), and Union Pacific (UNP).
Novartis (NVS) Gets Positive CHMP Opinion for Scemblix in CML
by Zacks Equity Research
The CHMP recommends approval of Novartis' (NVS) Scemblix for treating adult patients with chronic myeloid leukemia. EU also approves label expansion of Cosentyx.
Pharma Stock Roundup: FDA OK's Expanded Use of ABBV, MRK, NVS Drugs, Other Updates
by Kinjel Shah
The FDA approves expanded use of AbbVie's (ABBV) Skyrizi, Merck's (MRK) Vaxneuvance vaccine and Novartis's (NVS) cancer combination drugs, Tafinlar (dabrafenib) + Mekinist (trametinib).
Novartis' (NVS) Oncology Drugs Get Approval for Label Expansion
by Zacks Equity Research
Novartis (NVS) obtains regulatory approval for label expansion of Tafinlar + Mekinist and Tabrecta.
Precision BioSciences' (DTIL) Stock Up This Week: Here's Why
by Zacks Equity Research
Shares of Precision BioSciences (DTIL) are up as the company inks a gene-editing deal with Novartis to develop a potentially curative treatment for disorders like sickle cell disease.
Ionis (IONS), AstraZeneca's Amyloidosis Drug Meets Study Goals
by Zacks Equity Research
Ionis (IONS), along with partner AstraZeneca, reports positive data from a phase III study, which is evaluating eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
Amgen (AMGN) Olpasiran Lowers Lipoprotein Levels in Phase II
by Zacks Equity Research
Amgen's (AMGN) olpasiran, a small interfering RNA molecule, is designed in such a way that it lowers the body's production of apolipoprotein(a), a key component of Lp(a) which increases the risk of cardiovascular events.
Roche's (RHHBY) Evrysdi Gets FDA Nod for Label Extension
by Zacks Equity Research
The FDA approves a label expansion of Roche's (RHHBY) SMA drug Evrysdi to include less than two-month old babies with SMA.
Novartis (NVS) Wins FDA Nod for Label Expansion of Kymriah
by Zacks Equity Research
Novartis' (NVS) CAR-T cell therapy Kymriah (tisagenlecleucel) gets an FDA approval for a third indication.
The Zacks Analyst Blog Highlights Bank of America, Novo Nordisk, Novartis, Analog Devices and Sony Group
by Zacks Equity Research
Bank of America, Novo Nordisk, Novartis, Analog Devices and Sony Group have been included in this Analyst Blog.
Top Analyst Reports for Bank of America, Novo Nordisk, & Novartis
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corporation (BAC), Novo Nordisk A/S (NVO), and Novartis AG (NVS).
Novartis (NVS) Cosentyx Gets Positive CHMP Opinion for JIA
by Zacks Equity Research
Novartis (NVS) Cosentyx gets a positive CHMP recommendation for the indication of juvenile idiopathic arthritis.
Alnylam's (ALNY) Marketed Drugs Aid Growth Amid Competition
by Zacks Equity Research
Alnylam's (ALNY) portfolio of approved drugs is witnessing strong uptake so far while its pipeline is progressing well. However, stiff competition in the target market remains a woe.
Deciphera (DCPH) Down Despite Narrower-Than-Expected Q1 Loss
by Zacks Equity Research
Deciphera (DCPH) reports narrower-than-expected loss in the first quarter of 2022 while revenues beat estimates.
Iovance (IOVA) Q1 Earnings Beat, Lifileucel BLA on Track
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) reports a narrower-than-expected first-quarter loss. The company is on track to file a regulatory submission for lifileucel in melanoma in August 2022.
Ionis (IONS) Q1 Earnings & Sales Beat Estimates, Stock Rises
by Zacks Equity Research
Ionis (IONS) incurs a narrower-than-expected loss in Q1. Its sales also come ahead of estimates. Stock moves up in response to the results.
Incyte's (INCY) Q1 Earnings and Revenues Fall Shy of Estimates
by Zacks Equity Research
Incyte's (INCY) earnings and revenues miss estimates in the first quarter of 2022. The company raises the bottom end of full-year Jakafi net product revenue guidance.
Alnylam (ALNY) Misses on Q1 Earnings, Lowers '22 Revenue View
by Zacks Equity Research
Alnylam's (ALNY) earnings and sales fall shy of estimates in the first quarter of 2022. The company cuts 2022 guidance for net product revenues. Shares down.
Pharma Stock Roundup: Q1 Earnings of LLY, MRK & NVS, FDA Updates for AZN & PFE
by Kinjel Shah
Eli Lilly (LLY), Merck (MRK), Novartis (NVS) and others announce Q1 results. FDA updates for AstraZeneca (AZN) and Pfizer (PFE) grab headlines in the pharma space.
Drug/Biotech Stocks Q1 Earnings Due on Apr 29: BMY, ABBV, AZN
by Zacks Equity Research
Let us take a look at what is in store for BMY, ABBV, and AZN that are scheduled to report on Apr 29.
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte's (INCY) top line is likely to have been driven in the first quarter by the sales of its lead drug, Jakafi.
Novartis (NVS) Beats on Q1 Earnings, Sandoz Posts Growth
by Zacks Equity Research
Novartis (NVS) beats on earnings in the first quarter but sales lag expectations. Generic Sandoz business returns to growth.